Title: Hepatocyte growth factor renders BRAF mutant human melanoma cell lines resistant to PLX4032 by downregulating the pro-apoptotic BH3-only proteins PUMA and BIM.
Journal: Cell death and differentiation 20161201
Title: Cytokines can counteract the inhibitory effect of MEK-i on NK-cell function.
Journal: Oncotarget 20160920
Title: Role of the protein kinase BRAF in the pathogenesis of endometriosis.
Journal: Expert opinion on therapeutic targets 20160801
Title: BET and BRAF inhibitors act synergistically against BRAF-mutant melanoma.
Journal: Cancer medicine 20160601
Title: HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors.
Journal: Cancer research 20160501
Title: Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours.
Journal: British journal of cancer 20160315
Title: Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation.
Journal: The EMBO journal 20160301
Title: Robust Thyroid Gene Expression and Radioiodine Uptake Induced by Simultaneous Suppression of BRAF V600E and Histone Deacetylase in Thyroid Cancer Cells.
Journal: The Journal of clinical endocrinology and metabolism 20160301
Title: p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.
Journal: European journal of cancer (Oxford, England : 1990) 20160301
Title: MAPK and SHH pathways modulate type 3 deiodinase expression in papillary thyroid carcinoma.
Journal: Endocrine-related cancer 20160301
Title: Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b.
Journal: Oncotarget 20160126
Title: Melanoma Expressed-CD70 Is Regulated by RhoA and MAPK Pathways without Affecting Vemurafenib Treatment Activity.
Journal: PloS one 20160101
Title: Mechanisms Underpinning Increased Plasma Creatinine Levels in Patients Receiving Vemurafenib for Advanced Melanoma.
Journal: PloS one 20160101
Title: Paradoxical activation of MEK/ERK signaling induced by B-Raf inhibition enhances DR5 expression and DR5 activation-induced apoptosis in Ras-mutant cancer cells.
Journal: Scientific reports 20160101
Title: Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors.
Journal: Cancer chemotherapy and pharmacology 20151101
Title: RAF inhibitors that evade paradoxical MAPK pathway activation.
Journal: Nature 20151022
Title: Photoactivatable Prodrugs of Antimelanoma Agent Vemurafenib.
Journal: ACS chemical biology 20150918
Title: Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.
Journal: Cancer cell 20150914
Title: Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.
Journal: Chemical research in toxicology 20150518
Title: The quinone methide aurin is a heat shock response inducer that causes proteotoxic stress and Noxa-dependent apoptosis in malignant melanoma cells.
Journal: The Journal of biological chemistry 20150116
Title: Perturbation biology nominates upstream-downstream drug combinations in RAF inhibitor resistant melanoma cells.
Journal: eLife 20150101
Title: PLX4032 Mediated Melanoma Associated Antigen Potentiation in Patient Derived Primary Melanoma Cells.
Journal: Journal of Cancer 20150101
Title: Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
Journal: Journal of medicinal chemistry 20141009
Title: Identification of recurrent SMO and BRAF mutations in ameloblastomas.
Journal: Nature genetics 20140701
Title: Copper is required for oncogenic BRAF signalling and tumorigenesis.
Journal: Nature 20140522
Title: Characterization of vemurafenib phototoxicity in a mouse model.
Journal: Toxicological sciences : an official journal of the Society of Toxicology 20140101
Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.
Journal: Bioorganic & medicinal chemistry letters 20130801
Title: Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.
Journal: Expert opinion on drug metabolism & toxicology 20130701
Title: BRAF inhibitor activity in V600R metastatic melanoma.
Journal: European journal of cancer (Oxford, England : 1990) 20130301
Title: A multisite blinded study for the detection of BRAF mutations in formalin-fixed, paraffin-embedded malignant melanoma.
Journal: Scientific reports 20130101
Title: Vemurafenib for the treatment of melanoma.
Journal: Expert opinion on pharmacotherapy 20121201
Title: Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
Journal: Molecular pharmaceutics 20121105
Title: Cytotoxicity of new duplex drugs linking 3'-C-ethynylcytidine and 5-fluor-2'-deoxyuridine against human melanoma cells.
Journal: International journal of cancer 20121101
Title: Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities.
Journal: The British journal of dermatology 20121101
Title: Successful desensitization in a case of Stevens-Johnson syndrome due to vemurafenib.
Journal: Melanoma research 20121001
Title: Vemurafenib: in unresectable or metastatic melanoma.
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 20121001
Title: Conformation-specific effects of Raf kinase inhibitors.
Journal: Journal of medicinal chemistry 20120913
Title: Combining pharmacophore, docking and substructure search approaches to identify and optimize novel B-RafV600E inhibitors.
Journal: Bioorganic & medicinal chemistry letters 20120901
Title: How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20120901
Title: From chemotherapy to targeted treatment.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20120901
Title: Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.
Journal: Nature 20120726
Title: Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032).
Journal: The Journal of pharmacology and experimental therapeutics 20120701
Title: Design, synthesis, and antiproliferative activity of new 1H-pyrrolo[3,2-c]pyridine derivatives against melanoma cell lines. Part 2.
Journal: Bioorganic & medicinal chemistry letters 20120701
Title: Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
Journal: Clinical therapeutics 20120701
Title: Receptor tyrosine kinases in cancer escape from BRAF inhibitors.
Journal: Cell research 20120601
Title: Early [18F]fluorodeoxyglucose-positron emission tomography responses in metastatic melanoma: what do they mean?
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120510
Title: Narrowing the knowledge gaps for melanoma.
Journal: Upsala journal of medical sciences 20120501
Title: New diarylureas and diarylamides possessing acet(benz)amidophenyl scaffold: design, synthesis, and antiproliferative activity against melanoma cell line.
Journal: Bioorganic & medicinal chemistry letters 20120501
Title: BRIM-1, -2 and -3 trials: improved survival with vemurafenib in metastatic melanoma patients with a BRAF(V600E) mutation.
Journal: Future oncology (London, England) 20120501
Title: Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor.
Journal: Future oncology (London, England) 20120501
Title: A case of vemurafenib-induced keratosis pilaris-like eruption.
Journal: Dermatology online journal 20120415
Title: Upcoming strategies for the treatment of metastatic melanoma.
Journal: Archives of dermatological research 20120401
Title: Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor vemurafenib in human and mouse plasma.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120315
Title: Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management.
Journal: Archives of dermatology 20120301
Title: Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights.
Journal: Current opinion in oncology 20120301
Title: Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma.
Journal: Archives of dermatology 20120301
Title: Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.
Journal: The New England journal of medicine 20120223
Title: Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.
Journal: Cancer research 20120215
Title: The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells.
Journal: The Journal of clinical endocrinology and metabolism 20120201
Title: Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Journal: Cancer research 20120201
Title: Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.
Journal: Nature 20120126
Title: RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120120
Title: Drug approvals 2011: focus on companion diagnostics.
Journal: Journal of the National Cancer Institute 20120118
Title: Small molecule inhibitors of BRAF in clinical trials.
Journal: Bioorganic & medicinal chemistry letters 20120115
Title: Challenges ahead for companion diagnostics.
Journal: Journal of the National Cancer Institute 20120104
Title: Vemurafenib and BRAF inhibition: a new class of treatment for metastatic melanoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20120101
Title: Specifically targeting ERK1 or ERK2 kills melanoma cells.
Journal: Journal of translational medicine 20120101
Title: Long-term survival in metastatic malignant melanoma: ipilimumab followed by vemurafenib in a patient with brain metastasis.
Journal: Internal medicine (Tokyo, Japan) 20120101
Title: [BRAF mutation: a novel approach in targeted melanoma therapy].
Journal: Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 20120101
Title: Anti-cancer drugs elicit re-expression of UDP-glucuronosyltransferases in melanoma cells.
Journal: PloS one 20120101
Title: RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).
Journal: Nature 20111215
Title: Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.
Journal: The Journal of clinical investigation 20111201
Title: Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032.
Journal: Neoplasia (New York, N.Y.) 20111201
Title: [Dacarbazine, a chemotherapeutic against metastatic melanoma and a reference drug for new treatment modalities].
Journal: Postepy higieny i medycyny doswiadczalnej (Online) 20111123
Title: Larger companies dominate cancer companion diagnostic approvals.
Journal: Nature biotechnology 20111108
Title: Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma.
Journal: The Annals of pharmacotherapy 20111101
Title: Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition.
Journal: The Journal of investigative dermatology 20111001
Title: New drugs in melanoma: it's a whole new world.
Journal: European journal of cancer (Oxford, England : 1990) 20110901
Title: Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition.
Journal: Cancer research 20110801
Title: Novel immunotherapeutic agents and small molecule antagonists of signalling kinases for the treatment of metastatic melanoma.
Journal: Drugs 20110709
Title: Strides in melanoma announced: maximizing value comes next.
Journal: Journal of the National Cancer Institute 20110706
Title: From genome to drugs: where do we stand?
Journal: Journal of the National Cancer Institute 20110706
Title: Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
Journal: The New England journal of medicine 20110630
Title: BRAF targeted therapy changes the treatment paradigm in melanoma.
Journal: Nature reviews. Clinical oncology 20110524
Title: A beta-camera integrated with a microfluidic chip for radioassays based on real-time imaging of glycolysis in small cell populations.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20110501
Title: Overcoming metastatic melanoma with BRAF inhibitors.
Journal: Archives of pharmacal research 20110501
Title: Early accelerated approval for highly targeted cancer drugs.
Journal: The New England journal of medicine 20110324
Title: BRAF as a target for cancer therapy.
Journal: Anti-cancer agents in medicinal chemistry 20110301
Title: Equipoise and the dilemma of randomized clinical trials.
Journal: The New England journal of medicine 20110203
Title: The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204).
Journal: Biochemical and biophysical research communications 20110128
Title: Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations.
Journal: Journal of translational medicine 20110101
Title: [Advances in clinical treatment of malignant melanoma: B-RAF kinase inhibition].
Journal: Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 20110101
Title: Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.
Journal: PloS one 20110101
Title: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.
Journal: Nature 20101216
Title: Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
Journal: Nature 20101216
Title: Inhibition of mutated BRAF in melanoma.
Journal: The New England journal of medicine 20101202
Title: Oncogenic RAF: a brief history of time.
Journal: Pigment cell & melanoma research 20101201
Title: PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas.
Journal: Pigment cell & melanoma research 20101201
Title: Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.
Journal: Nature 20100930
Title: Inhibition of mutated, activated BRAF in metastatic melanoma.
Journal: The New England journal of medicine 20100826
Title: PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma.
Journal: Current opinion in investigational drugs (London, England : 2000) 20100601
Title: PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells.
Journal: Pigment cell & melanoma research 20100401
Title: Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032.
Journal: Journal of translational medicine 20100101
Title: Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032.
Journal: Journal of translational medicine 20100101
Title: Bollag G, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature, 2010, 467(7315), 596-599.
Title: Yang H, et al. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res, 2010, 70(13), 5518-5527.
Title: Prahallad A, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature, 2012, 483(7387), 100-103.
Title: Shelledy L, et al. Vemurafenib: First-in-Class BRAF-Mutated Inhibitor for the Treatment of Unresectable or MetastaticMelanoma. J Adv Pract Oncol. 2015 Jul-Aug;6(4):361-5.
Title: Wang W, et al. Targeting Autophagy Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.J Clin Endocrinol Metab. 2017 Feb 1;102(2):634-643.
